76 related articles for article (PubMed ID: 26999330)
1. Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.
Bolomsky A; Schreder M; Hübl W; Zojer N; Hilbe W; Ludwig H
Leuk Lymphoma; 2016 Nov; 57(11):2516-25. PubMed ID: 26999330
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.
Suzuki K; Yano S; Nishiwaki K; Sano K; Shimada T; Yahagi Y; Ogasawara Y; Sugiyama K; Takahara S; Saito T; Kasama K; Minami J; Yokoyama H; Kamiyama Y; Katsube A; Masuoka H; Katori M; Machishima T; Ouchi A; Dobashi N; Kaito K; Usui N; Aiba K
Cancer Med; 2016 Nov; 5(11):3051-3058. PubMed ID: 27734595
[TBL] [Abstract][Full Text] [Related]
3. Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age.
Uesugi Y; Ikeda D; Fukumoto A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
Haematologica; 2024 May; 109(5):1593-1597. PubMed ID: 38031801
[No Abstract] [Full Text] [Related]
4. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Richardson PG; Zimmerman TM; Hofmeister CC; Talpaz M; Chanan-Khan AA; Kaufman JL; Laubach JP; Chauhan D; Jakubowiak AJ; Reich S; Trikha M; Anderson KC
Blood; 2016 Jun; 127(22):2693-700. PubMed ID: 27009059
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
[TBL] [Abstract][Full Text] [Related]
7. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
Gooding S; Edwards CM
Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Paiva B; Cedena MT; Puig N; Arana P; Vidriales MB; Cordon L; Flores-Montero J; Gutierrez NC; Martín-Ramos ML; Martinez-Lopez J; Ocio EM; Hernandez MT; Teruel AI; Rosiñol L; Echeveste MA; Martinez R; Gironella M; Oriol A; Cabrera C; Martin J; Bargay J; Encinas C; Gonzalez Y; Van Dongen JJ; Orfao A; Bladé J; Mateos MV; Lahuerta JJ; San Miguel JF;
Blood; 2016 Jun; 127(25):3165-74. PubMed ID: 27118453
[TBL] [Abstract][Full Text] [Related]
9. Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.
Bieghs L; Brohus M; Kristensen IB; Abildgaard N; Bøgsted M; Johnsen HE; Conover CA; De Bruyne E; Vanderkerken K; Overgaard MT; Nyegaard M
PLoS One; 2016; 11(4):e0154256. PubMed ID: 27111220
[TBL] [Abstract][Full Text] [Related]
10. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
[TBL] [Abstract][Full Text] [Related]
11. A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma.
Schieferdecker A; Oberle A; Thiele B; Hofmann F; Göthel M; Miethe S; Hust M; Braig F; Voigt M; von Pein UM; Koch-Nolte F; Haag F; Alawi M; Indenbirken D; Grundhoff A; Bokemeyer C; Bacher U; Kröger N; Binder M
Blood; 2016 Jun; 127(25):3202-14. PubMed ID: 27034429
[TBL] [Abstract][Full Text] [Related]
12. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
[TBL] [Abstract][Full Text] [Related]
13. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD
Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985
[TBL] [Abstract][Full Text] [Related]
15. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo.
Sgadari C; Farber JM; Angiolillo AL; Liao F; Teruya-Feldstein J; Burd PR; Yao L; Gupta G; Kanegane C; Tosato G
Blood; 1997 Apr; 89(8):2635-43. PubMed ID: 9108380
[TBL] [Abstract][Full Text] [Related]
16. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
[TBL] [Abstract][Full Text] [Related]
17. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
[TBL] [Abstract][Full Text] [Related]
18. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.
Fu J; Li S; Feng R; Ma H; Sabeh F; Roodman GD; Wang J; Robinson S; Guo XE; Lund T; Normolle D; Mapara MY; Weiss SJ; Lentzsch S
J Clin Invest; 2016 May; 126(5):1759-72. PubMed ID: 27043283
[TBL] [Abstract][Full Text] [Related]
20. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
Slørdahl TS; Abdollahi P; Vandsemb EN; Rampa C; Misund K; Baranowska KA; Westhrin M; Waage A; Rø TB; Børset M
Oncotarget; 2016 May; 7(19):27295-306. PubMed ID: 27036022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
